Gb Sciences To Showcase Novel Parkinson's Treatment on Worldwide Business with Kathy Ireland
Kathy Ireland and Andrea Small Howard (Photo Credit: GB Sciences)
LAS VEGAS, December 14, 2023 (VSNewsNetwork.com) - Gb Sciences, Inc., a biopharmaceutical research and development company, will be featured on Worldwide Business with Kathy Ireland® this Sunday, Dec. 17, at 5:30 p.m. ET on the Fox Business Network. The episode will focus on the company's innovative cannabinoid-based medication for Parkinson’s disease, highlighting its recent advancements and future goals.
Gb Sciences has recently completed a successful dose-response study supporting its cannabinoid-based therapy for Parkinson’s disease. Dr. Andrea Small-Howard, President and Chief Science Officer at Gb Sciences, will join the program to discuss the company's plant-inspired medications, including its groundbreaking treatment for Parkinson's disease.
Discussing the upcoming feature, Dr. Small-Howard said, “We are honored to share recent information about our first-in-class, cannabinoid-based treatment for the motor symptoms of Parkinson’s disease on Worldwide Business with Kathy Ireland®.”
She emphasized the company’s vision in reimagining traditional medicines by creating safe, effective, plant-inspired formulations aimed to be sold as U.S. FDA-approved drugs, stating: “Beyond that, Gb Sciences is reimagining traditional medicines by creating safe, effective, plant-inspired formulations to be sold as U.S. FDA-approved drugs. Gb Sciences is working towards the future of medicine, and we are thankful for the opportunity to share our mission on this platform.”
Gb Sciences' Parkinson’s medication utilizes cannabinoids synthesized by Purisys, LLC, a leader in pharmaceutical-grade cannabinoid supply. To address common swallowing difficulties in Parkinson’s patients, Gb Sciences has chosen Catalent Pharma’s Zydis® orally disintegrating tablets (ODT) for effective dosing.
The company plans to file an Investigational New Drug Application for its Parkinson's treatment as early as next year, marking the first steps towards clinical trials. With Parkinson’s disease being the second most common neurodegenerative disease, the market for its treatments is anticipated to grow significantly.
For more information about Gb Sciences and its innovative approaches to medical treatments, visit www.gbsciences.com.
Source: Gb Sciences via Newswire
